文献速递白血病

神经酰胺诱导的整合应激反应克服急性髓系白血病中的Bcl-2抑制剂耐药

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
PubMed 文献 · Blood · 2022-01-01

研究在急性髓系白血病(AML)细胞中通过抑制鞘氨醇激酶触发神经酰胺蓄积,经蛋白激酶R激活ATF4引发凋亡性整合应激反应(ISR),促进Noxa转录并降解Mcl-1;与Venetoclax联用可协同杀伤原代AML原始细胞(含Venetoclax耐药突变)及免疫表型白血病干细胞,并减少患者来源AML异种移植模型的白血病植入。

要点

  • 抑制鞘氨醇激酶使AML细胞神经酰胺蓄积,经蛋白激酶R-ATF4通路诱导凋亡性ISR。
  • ISR通过转录BH3-only蛋白Noxa并降解Mcl-1发挥促凋亡作用。
  • 与Venetoclax联用协同杀伤原代AML原始细胞(含耐药突变)及白血病干细胞,减少异种移植植入。

核心结论

  • 神经酰胺通过蛋白激酶R-ATF4轴诱导凋亡性ISR并降解Mcl-1,为增强Bcl-2抑制治疗AML等高Mcl-1依赖肿瘤提供临床前依据。

研究设计与样本

  • 研究在AML细胞中通过抑制鞘氨醇激酶触发神经酰胺蓄积,并在原代AML原始细胞及患者来源AML异种移植模型中评估效应。

主要发现

  • 抑制鞘氨醇激酶诱导神经酰胺蓄积,经蛋白激酶R激活ATF4,转录Noxa并降解Mcl-1。
  • 与Venetoclax联用协同杀伤原代AML原始细胞,包括携带Venetoclax耐药突变者及免疫表型白血病干细胞。
  • 联合处理减少患者来源AML异种移植模型中的白血病植入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inducing cell death by the sphingolipid ceramide is a potential anticancer strategy, but the underlying mechanisms remain poorly defined. In this study, triggering an accumulation of ceramide in acute myeloid leukemia (AML) cells by inhibition of sphingosine kinase induced an apoptotic integrated stress response (ISR) through protein kinase R-mediated activation of the master transcription factor ATF4. This effect led to transcription of the BH3-only protein Noxa and degradation of the prosurvival Mcl-1 protein on which AML cells are highly dependent for survival. Targeting this novel ISR pathway, in combination with the Bcl-2 inhibitor venetoclax, synergistically killed primary AML blasts, including those with venetoclax-resistant mutations, as well as immunophenotypic leukemic stem cells, and reduced leukemic engraftment in patient-derived AML xenografts. Collectively, these findings provide mechanistic insight into the anticancer effects of ceramide and preclinical evidence for new approaches to augment Bcl-2 inhibition in the therapy of AML and other cancers with high Mcl-1 dependency.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lewis AC, Pope VS, Tea MN, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022. PMID: 35443029. doi:10.1182/blood.2021013277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。